A Study to Evaluate the Efficacy & Safety of CT-P27 in an Influenza

Clinical Trial Description

This study is a Randomised, Double-Blind, Placebo-Controlled, Single-Centre, Phase IIa study. All enrolled subjects will be given a single dose of 10 mg/kg CT-P27, 20 mg/kg CT-P27, or placebo intravenously and then followed by Day 36. ;

Study Design

See also
Status	Clinical Trial	Phase
Completed	`NCT03999554` - Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines	Phase 1
Completed	`NCT02487173` - Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B	N/A
Completed	`NCT01701752` - Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults	Phase 1
Enrolling by invitation	`NCT03207152` - Biomarkers Predicting Infectivity in an Experimental Human Influenza Model	Phase 1
Terminated	`NCT05567783` - A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A	Phase 2
Not yet recruiting	`NCT00987012` - The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients	N/A
Not yet recruiting	`NCT05928507` - FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
Completed	`NCT03651544` - The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac	Phase 1
Completed	`NCT02623322` - A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults	Phase 2
Completed	`NCT03196661` - Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population	Phase 1
Recruiting	`NCT06160531` - Influenza Viral Challenge Study of CC-42344 in Healthy Participants	Phase 2
Recruiting	`NCT06191393` - SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings	N/A
Recruiting	`NCT06127108` - Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel	N/A
Completed	`NCT05163730` - Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel	N/A
Recruiting	`NCT04896853` - Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®	Phase 1
Not yet recruiting	`NCT05787444` - Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)
Completed	`NCT05354115` - Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.	N/A
Completed	`NCT02014870` - Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers	Phase 1
Not yet recruiting	`NCT05897515` - LIAISON NES Flu A/B & COVID-19 Clinical Agreement	N/A
Completed	`NCT02767414` - Validation of the Ellume® Respirio Flu Test and the Ellume® eLab Flu Test for the Rapid Identification of Influenza A/B	N/A

NCT number	NCT02071914
Study type	Interventional
Source	Celltrion
Contact
Status	Completed
Phase	Phase 2
Start date	February 15, 2014
Completion date	June 19, 2014

A Study to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms